- Home
- WRLD vs ALT Comparison
WRLD vs ALT Comparison
Compare WRLD & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WRLD | ALT |
|---|---|---|
| Founded | 1962 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.3M | 576.0M |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | WRLD | ALT |
|---|---|---|
| Price | $145.31 | $5.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.33 |
| AVG Volume (30 Days) | 89.8K | ★ 3.5M |
| Earning Date | 01-27-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.75 | N/A |
| Revenue | ★ $570,762,378.00 | $20,000.00 |
| Revenue This Year | $0.89 | N/A |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | $13.80 | ★ N/A |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $104.99 | $2.90 |
| 52 Week High | $185.48 | $9.59 |
Technical Indicators
Market Signals| Indicator | WRLD | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 62.39 |
| Support Level | $137.15 | $5.03 |
| Resistance Level | $150.68 | $6.03 |
| Average True Range (ATR) | 7.15 | 0.38 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 33.69 | 53.39 |
Price Performance
Historical ComparisonAbout WRLD World Acceptance Corporation
World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.